Clinical Trial

Colchicine Versus Placebo After Pulmonary Vein Isolation

Study Description

Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)

Recurrence is a common problem after catheter ablation for atrial fibrillation, affecting at least one out of three patients. Inflammation due to the procedure may contribute to pulmonary vein reconnection and, thus, failure of catheter ablation. This pilot study will assess whether a randomized, placebo-controlled, double-blind trial investigating a 10-day treatment with colchicine, a potent anti-inflammatory drug, to improve patient relevant outcomes after catheter ablation for atrial fibrillation is feasible.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Colchicine 0.6 mg

p.o. twice daily for 10 days after catheter ablation for atrial fibrillation

Drug - Matching placebo

p.o. twice daily for 10 days after catheter ablation for atrial fibrillation

Additional Information

Official Study Title

Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI): A Pilot Study

Clinical Trial ID

NCT04160117

ParticipAid ID

eZ676e